American Journal of Cardiovascular Drugs
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
Perindopril/Amlodipine (Prestalia®): A Review in Hypertension
American Journal of Cardiovascular Drugs - Tập 15 - Trang 363-370 - 2015
Perindopril, an ACE inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, are established antihypertensive agents with complementary mechanisms of action. Recently, a once-daily, orally-administered, fixed-dose combination (FDC) of perindopril arginine plus amlodipine besylate (Prestalia®; hereafter referred to as perindopril/amlodipine FDC) was approved in the USA for the treatmen...... hiện toàn bộ
Statins and Aspirin: Do They Really Work in Women?
American Journal of Cardiovascular Drugs - Tập 15 - Trang 151-162 - 2015
Cardiovascular disease continues to be the most common cause of mortality in women in the USA. As a result, greater emphasis has been placed on preventive measures. Studies examining the role of aspirin and HMG-CoA reductase inhibitors (statins) have shown important clinical differences in men versus women in the preventive realm. This has led to inconsistent recommendations by guideline committee...... hiện toàn bộ
Alirocumab: A Review in Hypercholesterolemia
American Journal of Cardiovascular Drugs - Tập 16 - Trang 141-152 - 2016
Alirocumab (Praluent®) is a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) that is administered via subcutaneous injection every 2 weeks. Across ten phase III studies from the ODYSSEY clinical trial program in patients with heterozygous familial hypercholesterolemia (heFH) or nonfamilial hypercholesterolemia (nonFH), including some with mixed dyslipidemia, subcut...... hiện toàn bộ
Authors’ Reply to Rana et al. “Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials”
American Journal of Cardiovascular Drugs - - 2019
Management of Ischemic Heart Disease in Patients with Chronic Kidney Disease
American Journal of Cardiovascular Drugs - Tập 8 - Trang 219-231 - 2012
Patients with chronic kidney disease (CKD) and ischemic heart disease (IHD) have strikingly high mortality rates. In the general population, there has been a reduction in the mortality and morbidity rates for IHD through the implementation of effective risk-factor-reduction programs and better interventions for patients with established IHD. No such trend has been observed in patients with end-sta...... hiện toàn bộ
Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
American Journal of Cardiovascular Drugs - Tập 22 Số 1 - Trang 35-46 - 2022
Annual Congress of the European Society of Cardiology: August 27–31, 2016; Rome, Italy
American Journal of Cardiovascular Drugs - Tập 16 - Trang 469-472 - 2016
Ambrisentan
American Journal of Cardiovascular Drugs - Tập 11 - Trang 215-226 - 2012
Ambrisentan, an orally active, highly selective antagonist of the endothelin-1 type A receptor, is indicated for the treatment of pulmonary arterial hypertension (PAH). It has a low potential for drug-drug interactions and requires only once-daily administration. Three months’ treatment with ambrisentan 2.5–10 mg/day significantly improved exercise capacity, as determined by the distance walked in...... hiện toàn bộ
Pharmacoinvasive Approach with Streptokinase in Low to Intermediate Risk ST-Elevation Myocardial Infarction Patients: Insights from the Tamil Nadu-STEMI Initiative
American Journal of Cardiovascular Drugs - Tập 19 - Trang 517-519 - 2019
Epoprostenol (Veletri®, Caripul®): A Review of Its Use in Patients with Pulmonary Arterial Hypertension
American Journal of Cardiovascular Drugs - Tập 14 - Trang 463-470 - 2014
A bioequivalent formulation of intravenous epoprostenol containing the excipients arginine and sucrose (epoprostenol AS) (Veletri®, Caripul®) is approved in the USA, UK, and other countries for the treatment of pulmonary arterial hypertension (PAH), and has improved thermal stability compared with epoprostenol containing glycine and mannitol (epoprostenol GM) (Flolan®). Epoprostenol, a synthetic p...... hiện toàn bộ
Tổng số: 797
- 1
- 2
- 3
- 4
- 5
- 6
- 10